This study is for people with advanced lung cancer called **non-small cell lung cancer (NSCLC)**. The study compares two treatments: one with a combination of drugs, including N-803, *tislelizumab*, and *docetaxel*, and the other with just *docetaxel* alone. **Tislelizumab** and **docetaxel** are medicines used to help the body fight cancer. **N-803** is an experimental drug that might help the other medicines work better. - **Key Points:** - The study is conducted in two groups, and participants will be randomly placed into one of these groups. - Participants need to be at least 18 years old and have a specific type of lung cancer that has not responded to previous treatments. - The study involves regular visits and follow-up checks. Participants must agree to use contraception because the medications can affect pregnancies. Participants should consider their availability for required visits and their ability to follow the study's rules, including not being involved in other trials at the same time.